Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Our Participating Medicines

The Genentech medicines supported by the Genentech Patient Foundation are:

  • Actemra® (tocilizumab)
  • Activase® (alteplase)
  • Alecensa® (alectinib)
  • Avastin® (bevacizumab)
  • Cathflo Activase® (alteplase)
  • Cotellic® (cobimetinib)
  • Enspryng (satralizumab-mwge)
  • Erivedge® (vismodegib)
  • Esbriet® (pirfenidone)
  • Evrysdi (risdiplam)
  • Gazyva® (obinutuzumab)
  • Gavreto (Pralsetinib)
  • Hemlibra® (emicizumab-kxwh)
  • Herceptin® (trastuzumab)
  • Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)
  • Kadcyla® (ado-trastuzumab emtansine)
  • Lucentis (ranibizumab injection)
  • Ocrevus® (ocrelizumab)
  • Pegasys® (peginterferon alfa-2a)
  • Perjeta® (pertuzumab)
  • Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
  • Polivy (polatuzumab vedotin-piiq)
  • Pulmozyme® (dornase alfa)
  • Rituxan® (rituximab)
  • Rituxan Hycela (rituximab and hyaluronidase human)
  • Rozlytrek (entrectinib)
  • Tecentriq® (atezolizumab)
  • TNKase® (tenecteplase)
  • Venclexta® (venetoclax)
  • Xeloda® (capecitabine)
  • Xolair® (omalizumab)
  • Zelboraf® (vemurafenib)

Please Note: At this time, the Genentech Patient Foundation uses a separate process to support the following medicines:

  • CELLCEPT® (mycophenolate mofetil)
  • FUZEON® (enfuvirtide)
  • NUTROPIN AQ® (somatropin)
  • VALCYTE® (valganciclovir hydrochloride)

Learn more about support programs for these Genentech medicines here.

If you have been prescribed a participating medicine, you may qualify for support from the Genentech Patient Foundation. View the 'See If You Qualify' page to determine eligibility.


Support for Genentech medicines not listed above:

If you do not see your medicine listed, please contact our Patient Resource Center at 1 (877) GENENTECH (436-3683) for more information.